Skip to main content



10-24-2017 | Pioglitazone | News

Patients treated with pioglitazone may have reduced gout risk

Observational findings suggest that pioglitazone use may be associated with a reduced risk for gout among patients with diabetes.

09-13-2017 | Pioglitazone | EASD 2017 | News

TOSCA.IT: Similar long-term CV safety profile for pioglitazone, sulfonylurea

 The TOCSA.IT investigators have found no differences in cardiovascular disease outcomes between patients with type 2 diabetes taking pioglitazone versus sulfonylurea over nearly 5 years.

08-03-2017 | Ipragliflozin | News

Ipragliflozin and pioglitazone ‘equally beneficial’ for type 2 diabetes with NAFLD

Results of a randomized trial suggest that the sodium-glucose cotransporter 2 inhibitor ipragliflozin has equivalent efficacy to pioglitazone for the treatment of patients with type 2 diabetes complicated by nonalcoholic fatty liver disease.

Read more

Related topics



Journal articles and book chapters

10-23-2017 | Insulin | Review | Article

Insulin and its cardiovascular effects: What is the current evidence?

This review discusses the key factors implicated in development and progression of cardiovascular disease, its relationship to insulin therapy, and what can be learned from large, recent cardiovascular outcome studies.

Dongerkery SP, Schroeder PR, Shomali ME. Curr Diab Rep 2017;17:120. doi:10.1007/s11892-017-0955-3

10-23-2017 | Cardiovascular disorders | Review | Article

Translating recent results from the Cardiovascular Outcomes Trials into clinical practice: Recommendations from the Central and Eastern European Diabetes Expert Group (CEEDEG)

The authors develop regional expert consensus recommendations with aim of improving the care of patients with type 2 diabetes at high cardiovascular risk in Central and Eastern Europe.

Schernthaner G et al. Cardiovasc Diabetol 2017;16:137. doi:10.1186/s12933-017-0622-7

09-27-2017 | Dyslipidemia | Review | Article

Treatment of dyslipidemia in diabetes: Recent advances and remaining questions

This review summarizes the current knowledge concerning diabetic dyslipidemia and cardiovascular disease (CVD), including specific strategies to reduce diabetes-associated CVD.

Chait A, Goldberg I. Curr Diab Rep 2017;17:112. doi:10.1007/s11892-017-0942-8